Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
5.87
+0.17 (2.98%)
At close: Apr 14, 2026, 4:00 PM EDT
5.98
+0.11 (1.87%)
After-hours: Apr 14, 2026, 4:32 PM EDT
Minerva Neurosciences Employees
Minerva Neurosciences had 7 employees as of December 31, 2025. The number of employees decreased by 1 or -12.50% compared to the previous year.
Employees
7
Change (1Y)
-1
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$41,917,597
Market Cap
254.02M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | -1 | -12.50% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | 0 | - |
| Dec 31, 2021 | 9 | -2 | -18.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 147 |
| Adagene | 128 |
| Arcturus Therapeutics Holdings | 111 |
| Alector | 103 |
| Orchestra BioMed Holdings | 86 |
| Compugen | 75 |
| Camp4 Therapeutics | 48 |
| ALX Oncology Holdings | 43 |
NERV News
- 12 days ago - Minerva Announces Leadership Transition - GlobeNewsWire
- 14 days ago - Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - GlobeNewsWire
- 20 days ago - Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - GlobeNewsWire
- 4 weeks ago - Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - GlobeNewsWire
- 4 weeks ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 5 weeks ago - Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - GlobeNewsWire
- 5 months ago - Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors - GlobeNewsWire